Hilton Pharma (Pvt) Limited.
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer and marketer · Karachi · Pakistan
Pakistan pharmaceutical company manufacturing and marketing branded generics and licensed products, with human and animal health portfolios.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Hilton Pharma (Pvt.) Limited
- Company type
- Private pharmaceutical manufacturer and marketer
- Address
- Progressive Plaza, 8-9th Floor, Beaumont Road, Near P.I.D.C House, Karachi, Pakistan
- Website
- hiltonpharma.com ↗
- Phone
- +92 21 111 123 000
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Hilton Pharma (Pvt) Limited. is priced against the market
230 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| LERACE | Levetiracetam | 100 mg/mL | Oral solution | 120ml | 061224 | PKR 1,540.13 | PKR 12.83/mL | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 100 mg/mL | Oral solution | 30ml | 061224 | PKR 488.72 | PKR 16.29/mL | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 100 mg/mL | Oral solution | 60ml | 061224 | PKR 887.72 | PKR 14.80/mL | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 100 mg/mL | Oral solution | 10ml | 061224 | PKR 145.46 | PKR 14.55/mL | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 500 mg/5 mL | Injection | 10's | 066949 | PKR 6,047.15 | PKR 604.72/vial/unit | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 500 mg/5 mL | Injection | 1's | 066949 | PKR 733.08 | PKR 733.08/vial/unit | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 500 mg | Extended-release tablet | 2x14's | 070417 | PKR 3,409.69 | PKR 121.77/tablet | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 500 mg | Tablet | 10's | 070417 | PKR 1,242.60 | PKR 124.26/tablet | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 500 mg | Tablet | 20's | 070417 | PKR 2,268.91 | PKR 113.45/tablet | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 500 mg | Tablet | 30's | 070417 | PKR 3,578.68 | PKR 119.29/tablet | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 500 mg | Extended-release tablet | 14's | 070417 | PKR 1,739.64 | PKR 124.26/tablet | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 750 mg | Tablet | 30's | 107780 | PKR 3,667.49 | PKR 122.25/tablet | 🔒 Pharma Pro |
| LERACE | Levetiracetam | 750 mg | Tablet | 10's | 107780 | PKR 1,273.55 | PKR 127.36/tablet | 🔒 Pharma Pro |
| LOJIN | Lamotrigine = | 25 mg | Tablet | 3 × 10's | 034408 | PKR 793.48 | PKR 26.45/tablet | 🔒 Pharma Pro |
| LOJIN | Lamotrigine = | 50 mg | Tablet | 3 × 10's | 034409 | PKR 1,124.63 | PKR 37.49/tablet | 🔒 Pharma Pro |
| LOJIN | Lamotrigine = | 100 mg | Tablet | 30's | 037192 | PKR 1,554.85 | PKR 51.83/tablet | 🔒 Pharma Pro |
| LOJIN | Lamotrigine = | 150 mg | Tablet | 30's | 037193 | PKR 1,166.49 | PKR 38.88/tablet | 🔒 Pharma Pro |
| LOJIN | Lamotrigine = | 200 mg | Tablet | 30's | 037194 | PKR 1,360.90 | PKR 45.36/tablet | 🔒 Pharma Pro |
| LOJIN | Lamotrigine = | 5 mg | Tablet | 3 × 10's | 039280 | PKR 97.20 | PKR 3.24/tablet | 🔒 Pharma Pro |
| LOJIN | Lamotrigine = | 5 mg | Tablet | 3 × 10's | 055135 | PKR 97.20 | PKR 3.24/tablet | 🔒 Pharma Pro |
| LOPIGAR | Clopidogrel | 75 mg | Tablet | 14's | 031116 | PKR 381.02 | PKR 27.22/tablet | 🔒 Pharma Pro |
| MEGADOX | Doxycycline | 100 mg | Capsule | 1's strip | 008354 | PKR 10.75 | — | No comparator |
| MEGADOX | Doxycycline | 100 mg | Capsule | 50's (bottle) | 008354 | PKR 516.01 | PKR 10.32/capsule | 🔒 Pharma Pro |
| MEVAC-FLU VACCINESource observed | — | — | Prefilled syringe injection | 1's | 066200Official source ↗ | No indexed price | — | — |
| Migohil Tablets 10mgRegistry verified | Mirogabalin Besylate Eq. to Mirogabalin | — | — | — | 135191Official source ↗ | No indexed price | — | — |
| Migohil Tablets 15mgRegistry verified | Mirogabalin Besylate Eq. to Mirogabalin | — | — | — | 135190Official source ↗ | No indexed price | — | — |
| Migohil Tablets 2.5mgRegistry verified | Mirogabalin Besylate Eq. to Mirogabalin | — | — | — | 135192Official source ↗ | No indexed price | — | — |
| Migohil Tablets 5mgRegistry verified | Mirogabalin Besylate Eq.to Mirogabalin | — | — | — | 135189Official source ↗ | No indexed price | — | — |
| MYZINK CHEWABLE | Zinc | 20 mg | Tablet | 30's | 058046 | PKR 291.62 | PKR 9.72/tablet | 🔒 Pharma Pro |
| MYZINK CHEWABLE | Zinc | 10 mg | Tablet | 20's | 061218 | PKR 110.81 | PKR 5.54/tablet | 🔒 Pharma Pro |
| MYZINK CHEWABLE | Zinc | 10 mg | Tablet | 10's | 061218 | PKR 58.32 | PKR 5.83/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 400 mg | Tablet | 60's | 025625 | PKR 3,989.79 | PKR 66.50/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 400 mg | Tablet | 10's | 025625 | PKR 847.73 | PKR 84.77/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 400 mg | Tablet | 30's | 025625 | PKR 1,994.90 | PKR 66.50/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 600 mg | Tablet | 60's | 025626 | PKR 7,188.90 | PKR 119.82/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 600 mg | Tablet | 10's | 025626 | PKR 1,490.03 | PKR 149.00/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 600 mg | Tablet | 30's | 025626 | PKR 3,594.45 | PKR 119.82/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 500 mg | Tablet | 60 's | 073729 | PKR 5,042.73 | PKR 84.05/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 500 mg | Tablet | 10 's | 073729 | PKR 913.68 | PKR 91.37/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 500 mg | Tablet | 30 's | 073729 | PKR 2,521.36 | PKR 84.05/tablet | 🔒 Pharma Pro |
| NOVIA | Ribavirin | 200 mg | Tablet | 10's | 073731 | PKR 106.92 | PKR 10.69/tablet | 🔒 Pharma Pro |
| NUKOHIL (NUKIK) GUM | Nicotine Polacrilex e.q to Nicotine | 2 mg | Chewing gum | 20's | 044068 | PKR 583.20 | PKR 29.16/unit | No comparator |
| NUKOHIL (NUKIK) GUM | Nicotine Polacrilex e.q to Nicotine | 4 mg | Chewing gum | 20's | 044069 | PKR 972.00 | PKR 48.60/unit | No comparator |
| OMEZAC | Omeprazole | 20 mg | Capsule | 14's | 003233 | PKR 933.02 | PKR 66.64/capsule | 🔒 Pharma Pro |
| OZENTA | Oseltamivir | 75 mg | Capsule | 10'S | 042218 | PKR 2,120.48 | PKR 212.05/capsule | 🔒 Pharma Pro |
| PIVIR | Nevirapine | 200 mg | Tablet | 60's | 057767 | PKR 4,898.87 | PKR 81.65/tablet | 🔒 Pharma Pro |
| QUSEL | Quetiapine | 25 mg | Tablet | 30's | 037684 | PKR 1,013.17 | PKR 33.77/tablet | 🔒 Pharma Pro |
| QUSEL | Quetiapine | 100 mg | Tablet | 1 × 10's | 037685 | PKR 641.72 | PKR 64.17/tablet | 🔒 Pharma Pro |
| QUSEL | Quetiapine | 100 mg | Tablet | 20's | 037685 | PKR 2,076.05 | PKR 103.80/tablet | 🔒 Pharma Pro |
| QUSEL | Quetiapine | 200 mg | Tablet | 30's | 037690 | PKR 2,599.59 | PKR 86.65/tablet | 🔒 Pharma Pro |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.